illumigene CMV assay, illumipro-10
DeviceCMV assay for detection of CMV
NCT Number: NCT03251261
To evaluate the illumigene CMV assay, using the illumipro-10 with neonates (up to 21 days of age) saliva swabs
Looking for future studies?
Notify MeUp to 20 day
All sexes
Observational
The Prince of Wales Hospital, Randwick, New South Wales, Australia
Healthy volunteers accepted: Yes
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
CMV assay for detection of CMV
Time frame: within 30 days of sample collection
Test each sample for CMV detection
Meridian Bioscience, Inc.
Industry
Illumigene CMV Clinical Trial Protocol
Acronym: CMV
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT06034925
CMV, Transplant Complication
Charleston, South Carolina, United States
View Trial DetailsNCT05041426
CMV, Lung Transplant
Pittsburgh, Pennsylvania, United States
View Trial DetailsNCT03924219
CMV, Cytomegalovirus Infections
Stanford, California, United States
View Trial DetailsNCT07419204
CMV, Colitis
Ankara, Turkey (Türkiye)
View Trial Details